Meloxicam - GOV.UK
PL 31388/0003-4 UKPAR Alpex Pharma (UK) Ltd, Meloxicam 7.5mg and 15mg Orodispersible Tablets 7 MEDICAL ASSESSMENT Clinical Background Meloxicam is a non-steroidal anti-inflammatory drug of the oxicam family, with anti-
Download Meloxicam - GOV.UK
Information
Domain:
Source:
Link to this page:
Documents from same domain
The Human Medicines Regulations 2012 – …
www.mhra.gov.ukThe Human Medicines Regulations 2012 – description of each Part This document provides a brief overview of each Part of the Human Medicines Regulations 2012 …
FULTIUM -D 800 IU CAPSULES - GOV.UK
www.mhra.gov.ukVitamin D deficiency, with levels of 25(OH)D below 25nmol/L (10ng/ml), could result in the disease rickets (or osteomalacia). The disease resulting as a deficiency is considered to be due to malabsorption
GLYCOPYRRONIUM BROMIDE 0.2MG/ML …
www.mhra.gov.ukUKPAR Glycopyrronium Bromide 0.2 mg/ml Solution for Injection PL 00156/0115 1 GLYCOPYRRONIUM BROMIDE 0.2MG/ML SOLUTION FOR INJECTION (PL 00156/0115)
PL 00010/0643 - GOV.UK
www.mhra.gov.ukUKPAR Canesten HC Cream PL 00010/0643 6 All excipients comply with their respective European Pharmacopoeia monographs, except triceteareth-4-
Public Assessment Report UKPAR Canesten Combi …
www.mhra.gov.ukThis is a summary of the Public Assessment Report (PAR) for Canesten Combi Pessary & External Cream 500mg / 2% w/w pessary & cream (PL 00010/0653).
DCPAR for Ampicillin-Salbactam 1 g--0 5 and 2 g-1 g ...
www.mhra.gov.ukPAR Ampicillin/Sulbactam 1 g/0.5 g and 2 g/1 g powder for Solution for Injection or Infusion UK/H/4322/001-2/DC 1 Public Assessment Report Decentralised Procedure
Public Assessment Report Mutual Recognition …
www.mhra.gov.ukPAR Sayana 104mg/0.65ml Suspension for Injection UK/H/0960/001/MR 1 Public Assessment Report Mutual Recognition Procedure SAYANA 104MG/0.65ML SUSPENSION FOR INJECTION
Cefixime 400 mg Film-coated Tablets, PL 22805 …
www.mhra.gov.ukMHRA PAR; CEFIXIME 400 MG FILM-COATED TABLETS, PL 22805/0032-3 2 Lay summary The Medicines and Healthcare products Regulatory Agency …
Public Assessment Report Decentralised Procedure …
www.mhra.gov.ukPublic Assessment Report Decentralised Procedure LIOTHYRONINE SODIUM 20 MICROGRAM TABLETS (liothyronine sodium) Procedure No: UK/H/6516/001/DC
Perindopril/Indapamide 2mg/0.625mg and …
www.mhra.gov.ukUKPAR Perindopril/Indapamide 2mg/0.625 and 4mg/1.25mg Tablets PL 20092/0058-9 2 Perindopril/Indapamide 2mg/0.625mg and 4mg/1.25mg Tablets PL 20092/0058-9
Related documents
RESEARCH AND DEVELOPMENT M. PHARM …
maliba.edu.inRESEARCH AND DEVELOPMENT M. PHARM THESIS 2011-12 Pharmacology Sr. No. Project title Name of Student Name of Guide 1 Effectiveness of Boerhaaviadiffusa and Punicagranatum in experimental prostatic hyperplasia in rats.
JP ) NBD grades - 大连业建贸易有限公司
www.dalian-diligence.com*1laser diffraction Introduction Physical Properties of NBD New grade of L-HPC ! (Low-Substituted Hydroxypropyl Cellulose NF / JP ) *2 Specific surface area: BET method
Dissolution Testing of Orally Disintegrating Tablets
www.dissolutiontech.com8 Dissolution Technologies | MAY 2003 Orally Disintegrating Tablets … continued development,a target specification can be set for taste-masked drug to assure acceptable/consistent taste.
Review Article - Global Research Online
www.globalresearchonline.netVolume 6, Issue 2, January – February 2011; Article-005 ISSN 0976 – 044X International Journal of Pharmaceutical Sciences Review and Research.
Formulation and Evaluation of Fast Dissolving Oral …
www.imedpub.comFormulation dissolving Drug (%) F F 5 7
Orally Disintegrating Tablets: An Overview
www.japsonline.comEvren ALĞIN YAPAR / Journal of Applied Pharmaceutical Science 4 (02); 2014: 118-125 119 ODTs can be differed seconds to minutes related to their size and
The Effects of Crospovidone and Croscarmellose …
www.sphinxsai.comJuanita Tanuwijaya et al /Int.J.PharmTech Res.2013,5(4) 1592 Table 1. Formula of piroxicam nanoparticles ODT varying in the composition of superdisintegrants. Formulation Code Components (m g)
Related search queries
RESEARCH AND DEVELOPMENT M. PHARM, RESEARCH AND DEVELOPMENT M. PHARM THESIS 2011, Dissolution Testing of Orally Disintegrating Tablets, Orally Disintegrating Tablets, Article, Formulation and Evaluation of Fast, Formulation, Orally Disintegrating Tablets: An Overview, Effects of Crospovidone and Croscarmellose